ArticleInternational medical case reports journal2026
Stand-Alone Carboxytherapy Followed by Consolidation with Oral Hydrolyzed Marine Collagen Fragments: A Potential Sequential Bioregenerative Strategy for Hypertrophic Scars: A Case Report.
Article in International medical case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Carboxytherapy, via the Bohr effect, a denser dermal environment, and preserved fibroblast function, along with oral administration of bioactive marine collagen fragments that target fibroblasts, are regenerative strategies that could improve scar elasticity, thickness, and hydration. Their sequential combination might be an innovative approach. Methods: In March 2024, a 56-year-old woman began treatment of a large, hypertrophic, partially retracted post-surgical scar in the nasojugal area at the level of the right nasal wing. Ablative techniques were strictly contraindicated; therefore, a regenerative, restructuring approach via carboxytherapy was chosen. A six-session carboxytherapy cycle was performed from October 10, 2024 (T0) to April 3, 2025 (T6). Each session, performed every 15 days, lasted approximately 10 minutes (flow rate: 60 mL/min, 30-G needle, temperature 45°C). Evaluations were conducted after the third (T3) and last (T6) sessions, using the Antera 3D device (quantitative three-dimensional objective analysis of scar depth, texture, erythrosis, and pigmentation) and the POSAS investigator and subject scoring scales. A final injection of persistent hyaluronic acid was performed on April 3, 2025. To support and strengthen the normalization of the scarring process, the first of a twice-yearly oral cycle of hydrolyzed marine collagen fragments began on October 23, 2025. Results: Over the six-month carboxytherapy treatment cycle, the scarred skin area showed significant improvement toward a normal appearance. The vascularity POSAS score (observer component) decreased from 7 at baseline to 3 at T6; the thickness and flexibility scores improved from 5 to 2 and from 7 to 3, respectively. Additionally, the POSAS pain and itching scores (patient component) decreased from 6 to 1. Conclusion: Stand-alone carboxytherapy again appears to be an effective option for hypertrophic, structurally abnormal scars. While further investigations are underway, supplementation with hydrolyzed marine collagen fragments may help maintain the benefits of prior carboxytherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.